How New Methods Are Unlocking Decades of Archived Human Tissue for Single-Cell Analysis

For over a century, hospitals and pathology laboratories worldwide have preserved human tissue by immersing it in formaldehyde and embedding it in paraffin wax. This routine histological process has created vast global archives containing millions of biological samples from patients with cancer, inflammatory diseases, and numerous other conditions. These formalin-fixed, paraffin-embedded (FFPE) blocks are remarkably stable, allowing them to be stored at room temperature for decades while perfectly preserving the morphological structure of the tissue for microscopic examination.

However, the very chemical process that preserves the tissue's physical architecture acts as a molecular vault. Formalin fixation creates extensive cross-links between proteins and nucleic acids, which stabilizes the cell but severely degrades and fragments the fragile RNA molecules inside. For decades, this chemical damage has locked these invaluable archives away from the most advanced genomic technologies, forcing researchers to rely almost exclusively on fresh tissue for high-resolution molecular profiling.[2]

This degradation has historically rendered FFPE archives incompatible with modern single-cell RNA sequencing (scRNA-seq). Traditional scRNA-seq technologies, which have revolutionized our understanding of cellular heterogeneity, strictly require fresh or snap-frozen tissue to capture intact RNA molecules. These conventional methods specifically rely on capturing the poly-A tails of messenger RNA to generate a complete transcriptomic profile of an individual cell.

Because formalin fixation destroys these poly-A tails and fragments the RNA strands, applying standard single-cell sequencing to FFPE tissue results in massive data dropouts, low capture efficiency, and overwhelming technical noise. Consequently, researchers have been unable to retrospectively analyze the millions of clinically annotated samples stored in pathology departments, leaving a massive gap between the historical clinical data and modern genomic capabilities.[1][3]

Recently, a wave of methodological breakthroughs has begun to bypass these chemical limitations, effectively unlocking the FFPE archives. Rather than relying on the fragile poly-A tails, new sequencing approaches utilize targeted probe hybridization or random primer-based reverse transcription to capture the fragmented RNA.

By deploying specialized chemical probes that bind directly to short, specific RNA sequences within the preserved cells, these methods can reconstruct a highly sensitive transcriptomic profile even from highly degraded archival blocks. This shift from whole-transcriptome capture to targeted probe hybridization allows scientists to extract meaningful single-cell data without requiring perfectly intact RNA strands, fundamentally changing the utility of preserved pathology specimens.[2]

One of the most significant advancements in this space involves recovering whole, intact cells from FFPE tissue rather than merely isolating the cell nuclei. Earlier attempts to sequence preserved tissue often relied on extracting just the nucleus, as it is more resistant to preservation damage. However, nuclear isolation discards the cytoplasm, taking a substantial amount of RNA and biological information with it.

New dissociation protocols are now designed to gently release whole cells from the paraffin matrix while minimizing the loss of cytoplasmic material. By recovering the entire cell, researchers can sequence the cytoplasmic RNA alongside the nuclear RNA, capturing a much richer transcriptomic profile and successfully identifying rare cell types—such as neutrophils and adipocytes—that nuclear isolation alone typically misses.[2]

The evidence supporting these new FFPE sequencing methods is compelling, but it comes with transparent technical caveats. While probe-based methods achieve excellent concordance with fresh tissue in identifying cell types and broad gene expression pathways, they are inherently limited by the specific probes included in the assay.

Because researchers must pre-define the RNA sequences they are looking for, these targeted approaches may miss novel transcripts or unexpected genetic variations that a true whole-transcriptome sequencing method would catch. Furthermore, the computational analysis of this data requires rigorous quality control to distinguish true biological signals from the artifactual mutations and high dropout rates caused by the initial formalin cross-linking.[2][3]

Additionally, the physical age of the FFPE block and the specific type of formalin used during the initial preservation can significantly impact the quality of the recovered RNA. Studies indicate that while DNA and RNA can be extracted from decades-old blocks, samples older than ten years often yield markedly lower quality data, introducing a variable of uncertainty into long-term retrospective studies.

The duration of the initial formalin fixation—typically ranging from 6 to 24 hours—also plays a critical role; over-fixation can cause irreversible molecular damage, while under-fixation fails to halt cellular degradation. These variables mean that not every archived block will yield usable single-cell data, requiring researchers to carefully screen their historical cohorts.[2]

Despite these technical limitations, the ability to perform single-cell sequencing on FFPE tissue represents a paradigm shift in biomedical research. The true value of these archives lies in their clinical annotations. Unlike fresh tissue collected today, archived FFPE blocks come with decades of documented patient history, including disease progression, treatment responses, and ultimate survival outcomes.

By transforming millions of inert wax blocks into active genomic datasets, these new methods allow scientists to connect high-resolution molecular profiles directly to real-world clinical trajectories. This provides unprecedented access to rare pathologies and longitudinal disease stages that are nearly impossible to assemble prospectively, accelerating the development of precision medicine grounded in historically inaccessible human tissues.[1][2]

As these technologies mature, the integration of single-cell sequencing with archived pathology specimens is expected to democratize genomic research. Fresh-tissue studies require complex logistical coordination between operating rooms and sequencing labs, historically confining this research to well-resourced academic centers. FFPE-compatible methods eliminate this real-time constraint, allowing laboratories worldwide to sequence samples at their own pace using existing biobanks. By bridging the gap between a century of traditional pathology and the cutting edge of single-cell genomics, researchers are finally poised to read the molecular history locked within the wax.[2][3]